504 related articles for article (PubMed ID: 32849532)
1. Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus.
Liu L; Takeda K; Akkoyunlu M
Front Immunol; 2020; 11():1569. PubMed ID: 32849532
[TBL] [Abstract][Full Text] [Related]
2. Circulating CD138 enhances disease progression by augmenting autoreactive antibody production in a mouse model of systemic lupus erythematosus.
Liu L; Akkoyunlu M
J Biol Chem; 2021 Sep; 297(3):101053. PubMed ID: 34364875
[TBL] [Abstract][Full Text] [Related]
3. Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development.
Wang M; Chen H; Qiu J; Yang HX; Zhang CY; Fei YY; Zhao LD; Zhou JX; Wang L; Wu QJ; Zhou YZ; Zhang W; Zhang FC; Zhang X; Lipsky PE
J Autoimmun; 2020 May; 109():102440. PubMed ID: 32201226
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of transcription factor Blimp1 in systemic lupus erythematosus.
Luo J; Niu X; Liu H; Zhang M; Chen M; Deng S
Mol Immunol; 2013 Dec; 56(4):574-82. PubMed ID: 23911415
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
6. CD138 promotes the accumulation and activation of autoreactive T cells in autoimmune MRL/lpr mice.
Xie T; Liu X; Li P
Exp Ther Med; 2023 Dec; 26(6):568. PubMed ID: 37954119
[TBL] [Abstract][Full Text] [Related]
7. Reducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolism.
Richard EM; Thiyagarajan T; Bunni MA; Basher F; Roddy PO; Siskind LJ; Nietert PJ; Nowling TK
PLoS One; 2013; 8(9):e75175. PubMed ID: 24040398
[TBL] [Abstract][Full Text] [Related]
8. IL-21 receptor is required for the systemic accumulation of activated B and T lymphocytes in MRL/MpJ-Fas(lpr/lpr)/J mice.
Rankin AL; Guay H; Herber D; Bertino SA; Duzanski TA; Carrier Y; Keegan S; Senices M; Stedman N; Ryan M; Bloom L; Medley Q; Collins M; Nickerson-Nutter C; Craft J; Young D; Dunussi-Joannopoulos K
J Immunol; 2012 Feb; 188(4):1656-67. PubMed ID: 22231702
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoid prevents CD138 expression in T cells of autoimmune MRL/
Xie T; Liu H; Li P
Mol Med Rep; 2022 Jun; 25(6):. PubMed ID: 35514318
[TBL] [Abstract][Full Text] [Related]
10. Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.
Bökers S; Urbat A; Daniel C; Amann K; Smith KG; Espéli M; Nitschke L
J Immunol; 2014 Apr; 192(7):2994-3002. PubMed ID: 24600033
[TBL] [Abstract][Full Text] [Related]
11. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice.
Suh CH; Freed JH; Cohen PL
J Immunol; 2003 Feb; 170(4):2229-35. PubMed ID: 12574397
[TBL] [Abstract][Full Text] [Related]
12. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
13. Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
Chesnutt MS; Finck BK; Killeen N; Connolly MK; Goodman H; Wofsy D
Clin Immunol Immunopathol; 1998 Apr; 87(1):23-32. PubMed ID: 9576007
[TBL] [Abstract][Full Text] [Related]
14. Activation of autoreactive T cells that help nucleobindin-injected mice produce anti-DNA antibodies.
Kubota T; Watanabe N; Kaneko T; Satake F; Miura K; Kurosawa Y; Miyasaka N; Kanai Y
Immunol Lett; 2001 Jan; 75(2):111-5. PubMed ID: 11137134
[TBL] [Abstract][Full Text] [Related]
15. Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.
Park MJ; Baek JA; Choi JW; Jang SG; Kim DS; Park SH; Cho ML; Kwok SK
Front Immunol; 2021; 12():606024. PubMed ID: 33986739
[TBL] [Abstract][Full Text] [Related]
16. Calcium signaling in systemic lupus erythematosus T cells: a treatment target.
Kyttaris VC; Zhang Z; Kampagianni O; Tsokos GC
Arthritis Rheum; 2011 Jul; 63(7):2058-66. PubMed ID: 21437870
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma cell frequency and accumulation of abnormal syndecan-1plus T-cells in Igmu-deficient/lpr mice.
Seagal J; Leider N; Wildbaum G; Karin N; Melamed D
Int Immunol; 2003 Sep; 15(9):1045-52. PubMed ID: 12917256
[TBL] [Abstract][Full Text] [Related]
18. Anti-ANX A1 Antibody Therapy in MRL/lpr Murine Model of Systemic Lupus Erythematosus.
Bradyanova S; Mihaylova N; Chipinski P; Manassiev Y; Herbáth M; Kyurkchiev D; Prechl J; Tchorbanov AI
Arch Immunol Ther Exp (Warsz); 2021 Jul; 69(1):19. PubMed ID: 34322760
[TBL] [Abstract][Full Text] [Related]
19. The central and multiple roles of B cells in lupus pathogenesis.
Chan OT; Madaio MP; Shlomchik MJ
Immunol Rev; 1999 Jun; 169():107-21. PubMed ID: 10450512
[TBL] [Abstract][Full Text] [Related]
20. Deficient leptin signaling ameliorates systemic lupus erythematosus lesions in MRL/Mp-Fas lpr mice.
Fujita Y; Fujii T; Mimori T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Tanaka M; Masaki Y; Fukushima T; Okazaki T; Umehara H
J Immunol; 2014 Feb; 192(3):979-84. PubMed ID: 24391210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
